Ngwaahịa

Ntugharị ntụgharị nke mkpụrụ ndụ ABL1 na mkpụrụ ndụ BCR na-eme ka ngosipụta nke protein fusion oncogenic BCR-ABL1, nke na-akọwa ọrịa leukemia myeloid na-adịghị ala ala (CML), ọrịa myeloproliferative nke a na-ewere na ọ na-egbu egbu ruo mgbe mmalite nke ezinụlọ imatinib nke tyrosine kinase. ndị na-emechi ihe (TKI).Ka o sina dị, enweghị mmetụta nke mkpụrụ ndụ sel CML na ọgwụgwọ TKI na nkwụsi ike ma ọ bụ nke enwetara ka bụ ihe na-ebutekarị ọrịa na-adịgide adịgide na ọganihu oge mgbawa na-enweta na ndị ọrịa mgbe usoro ọgwụgwọ mbụ gachara.N'ebe a, anyị nyochara ọrụ ga-ekwe omume maka MAPK15/ERK8 kinase na BCR-ABL1-based autophagy, usoro bụ isi maka leukemogenesis na-ebute oncogene.N'okwu a, anyị gosipụtara ike nke MAPK15 iji nweta oncogene n'ụzọ anụ ahụ na vesicles autophagic, na-akwado echiche anyị nke ọrụ dị mkpa nke ndụ maka MAP kinase a na ntụgharị mgbaàmà site na oncogene a.N'ezie, site n'ịmepụta BCR-ABL1 na-egosi na sel HeLa na t aking uru nke a physiologically mkpa nlereanya maka mmadụ CML, ya bụ K562 mkpụrụ ndụ, anyị gosiri na BCR-ABL1-induced autophagy bụ onye ogbugbo site na MAPK15 site na ya ike imekọrịta na LC3-ezinụlọ. protein, nke dabere na LIR.N'ụzọ na-akpali mmasị, anyị nwekwara ike igbochi BCR-ABL1-induced autophagy site na usoro ọgwụ na-eme ka a kwụsị MAPK15, na-emepe ohere nke ime ihe na kinase a iji metụta autophagy na ọrịa na-adabere na ọrụ cellular a.N'ezie, iji kwado ohere nke usoro a, anyị gosipụtara na njedebe nke okwu MAPK15 endogenous gbochiri BCR-ABL1-based cell proliferation, in vitro, na tumor formation, in vivo, ya mere na-enye njikọ "druggable" akwụkwọ akụkọ n'etiti BCR-ABL1 na mmadụ CML.